China Medical System Holdings Limited (CMS) disclosed that it repurchased 400,000 ordinary shares on 09 June 2026 through on-exchange transactions. The shares were bought at prices ranging from HKD 10.23 to HKD 10.35, with a volume-weighted average cost of HKD 10.28 per share. The total cash outlay amounted to HKD 4.11 million.

Following the transaction, CMS’s issued share capital (excluding treasury shares) fell by 0.02 % to 2.434 billion shares, while treasury shares increased from 5.10 million to 5.50 million. All repurchased shares are being held as treasury stock; none have been cancelled.

The buyback was executed under the repurchase mandate approved on 23 April 2026, which authorises the company to buy back up to 243.95 million shares. Cumulative repurchases under this mandate now stand at 5.50 million shares, representing 0.23 % of the company’s issued share capital at the mandate date. Under Hong Kong listing rules, CMS is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, lasting until 09 July 2026.